Financials in USD. Standardized financial statements.
A compact view of how China SXT Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.74M | $1.93M | $1.97M | $2.60M | $4.78M | $5.16M | $7.01M | $7.02M | $4.88M | $3.72M |
| Revenue Growth? | -9.7% | -2.2% | -24.2% | -45.5% | -7.5% | -26.4% | -0.1% | +43.8% | +31.3% | 0.0% |
| Cost of Revenue? | $1.37M | $1.37M | $1.55M | $1.35M | $1.94M | $2.46M | $2.40M | $3.62M | $2.57M | $2.92M |
| Gross Profit? | $367,427 | $553,971 | $426,271 | $1.25M | $2.84M | $2.70M | $4.61M | $3.40M | $2.31M | $793,988 |
| Gross Margin? | +21.1% | +28.7% | +21.6% | +48.1% | +59.4% | +52.4% | +65.8% | +48.5% | +47.4% | +21.4% |
| Operating Expenses? | $3.05M | $3.07M | $6.03M | $6.44M | $5.04M | $4.04M | $2.84M | $1.77M | $709,819 | $584,847 |
| Operating Income? | -$2.68M | -$2.52M | -$5.61M | -$5.19M | -$2.20M | -$1.34M | $1.77M | $1.63M | $1.60M | $209,140 |
| EBITDA? | -$2.57M | -$2.35M | -$5.21M | -$5.05M | -$1.85M | -$1.01M | $1.98M | $1.76M | $1.70M | $298,105 |
| Income Before Tax | -$3.30M | -$3.10M | -$5.93M | -$5.41M | -$2.94M | -$10.39M | $1.79M | $1.63M | $1.58M | $188,725 |
| Income Tax Expense | $0 | $0 | $0 | $328,146 | -$192,683 | -$101,722 | $252,232 | $440,103 | $395,049 | $47,181 |
| Net Income? | -$3.30M | -$3.10M | -$5.93M | -$5.74M | -$2.75M | -$10.29M | $1.54M | $1.19M | $1.19M | $141,544 |
| EPS? | $-8.18 | $-3.57 | $-22.23 | $-137.92 | $-95.48 | $-832.08 | $149.67 | $100.01 | $99.80 | $112.00 |
| Diluted EPS? | $-8.18 | $-3.57 | $-22.23 | $-137.92 | $-95.48 | $-832.08 | $149.67 | $100.01 | $99.80 | $112.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality